FOx BIOSYSTEMS, one of HERAN Partner's portfolio companies, is breaking the limits in bioanalysis. With our fund: HERAN HealthTech Fund I, we are committed to investing in entrepreneurs that add significant value to healthcare. That's why we are proud to share the following news:
On March 18th 2021, FOx BIOSYSTEMS launched their new product.
The White FOx - A new generation biosensor with fiber-optic surface plasmon resonance
The innovative fiber-optic probe setup combines a fluidics-free dip-in protocol with the precision and speed of SPR. This approach eliminates the risk of clogging when using complex samples such as lysates, whole blood or large particles. The probes use a generic surface chemistry and can be switched easily to allow the detection of different target molecules, including antibodies, nanobodies, microvesicles, phage and small molecules, with a single device.
Label-free kinetic affinity data, whole blood analysis and sandwich assays: the White FOx is an all-in-one, easy-to-use benchtop instrument that can overcome current limitations in bioanalytics.
Are you curious to discover this White FOx?
Watch the video and read the press release
Even more curious to discover how FOx Biosystems is breaking the limits in bioanalysis?
Visit their new website
About FOx BIOSYSTEMS:
FOx BIOSYSTEMS is a dynamic Belgian company on a mission to revolutionize the life sciences and pharmacological research market with innovative real-time, label-free analysis products. The basis of our success is a novel fiber-optic-based surface plasmon resonance (FO-SPR) biosensor which enables our users to generate high-quality, cost-effective biomolecular data fast, and over a wide range of applications.The White FOx is ready to take its place in your high-tech lab.
